

**WAKE FOREST  
UNIVERSITY**

SCHOOL of MEDICINE  
THE BOWMAN GRAY CAMPUS  
OFFICE OF RESEARCH

<http://www.wfubmc.edu/or>

**ADMINISTRATION**

JAMES E. SMITH, PH.D.,  
ASSOCIATE DEAN FOR RESEARCH  
DAVID P. FREIDMEN, PH.D.,  
DEPUTY ASSOCIATE DEAN FOR RESEARCH  
CHARLES E. McCALL, M.D.,  
DEPUTY ASSOCIATE DEAN FOR RESEARCH  
MARCO PAHOR, M.D.,  
DEPUTY ASSOCIATE DEAN FOR RESEARCH  
SHEILA L. VRANA, PH.D.,  
ASSISTANT DEAN FOR RESEARCH  
VICKY ZICKMUND 66402  
PATTIE SMITH 60280  
ANGELA HORTON 62382  
SARAH MABIE 64548

**INSTITUTIONAL REVIEW BOARD (IRB)**

WESLEY BYERLY, PHARM.D., DIRECTOR  
FRANKIE FLETCHER 67252  
JEANNIE TULLOCK 64781  
AMANDA SHARPE 64542

**GRANTS ADMINISTRATION**

SHEILA L. VRANA, PH.D.,  
ASSISTANT DEAN FOR RESEARCH  
DAVID LYONS, PH.D.,  
RESEARCH ADMINISTRATOR  
AMY COMER 64549  
RYAN FAVREAU 35306  
KIM VARGAS 60780  
ANGELA HORTON 62382

**INTRAMURAL RESEARCH SUPPORT  
COMMITTEE (IRSC)**

NANCY MURRAY 62382

**ANIMAL CARE AND USE COMMITTEE (ACUC)**

BEVERLY GREENWOOD 63407

**INDUSTRY RELATIONS**

JEAN BRANNOCK, INDUSTRY RELATIONS OFFICER  
TERESA BUIE 62846

**OFFICE OF CLINICAL TRIALS RESEARCH**

JOHN F. BUTTERWORTH, IV, M.D., DIRECTOR, 38848

**ENVIRONMENTAL HEALTH AND SAFETY**

DAVID A. BROWN, DIRECTOR  
INFECTION CONTROL 69375  
RADIATION SAFETY 777-3180  
CHEMICAL SAFETY 777-3099  
RADIATION SAFETY COMMITTEE 777-3180

**ANIMAL RESOURCES PROGRAM**

JEANNE WALLACE, D.V.M., DIRECTOR AND  
ATTENDING VETERINARIAN  
BRUCE ROSE, M.S., M.B.A., OPERATIONS MANAGER  
JAN SNYDER 64560  
VICKIE HARDY, OPERATIONS MANAGER, FRIEDBERG CAMPUS  
61573

# PURSUIT

RESEARCH INFORMATION BULLETIN Vol. 16, No. 8 September 2002

## FACULTY RESEARCH AWARDS DAY

FRIDAY, SEPTEMBER 27, 2002

9:00 AM

### NUTRITION RESEARCH CENTER CONFERENCE ROOMS

Join your colleagues for the 6<sup>th</sup> Annual Wake Forest University Health Sciences Basic and Clinical Research Awards. William B. Applegate, M.D., M.P.H., Dean and Senior Vice President, will provide opening remarks and James E. Smith, Ph.D., Associate Dean for Research, will introduce the awardees. Following lectures by recipients, awards will be presented by Richard H. Dean, M.D., President and Chief Executive Officer. The awardees and lectures are as follows:

**New Investigator in Basic Sciences (Co-Recipient)**

Robert C. Coghill, Ph.D.  
"Neural Correlates of the Subjective Experience of Pain"

**New Investigator in Basic Sciences (Co-Recipient)**

Jeffrey L. Weiner, Ph.D.  
"Investigating the Drunken Synapse: What Can Electrophysiology Tell Us About Alcohol's Intoxicating Effects?"

**New Investigator in Clinical Sciences (Co-Recipient)**

Shari Barkin, M.D.  
"Office-Based Youth Violence Prevention"

**New Investigator in Clinical Sciences (Co-Recipient)**

Ronny A. Bell, Ph.D.  
"Issues in Native American Health: Opportunities for Epidemiologic Research"

**Established Investigator in Basic Sciences**

Kathleen A. Grant, Ph.D.  
"What's Brewing in Alcohol Research?"

**Established Investigator in Clinical Sciences**

Dixon M. Moody, M.D.  
"Microvascular Alterations in Degenerative Brain Disorders"

**Reception to follow ceremony in the Nutrition Research Center, Exhibit Hall, E Floor.**

**CONCERN LINES**

ANIMAL CARE & USE -  
716-5899  
RESEARCH CONDUCT -  
716-0338  
COMPLIANCE -  
1-877-880-7888

\*\*\*\*\*

**REGULATORY COMMITTEE  
DEADLINES**

ANIMAL CARE AND USE COMMITTEE -  
OCTOBER 4 AND NOVEMBER 1, 2002

INSTITUTIONAL REVIEW BOARD -  
NOON - FRIDAYS

\*\*\*\*\*

**INTRAMURAL RESEARCH  
SUPPORT COMMITTEE  
DEADLINES**

\*REGULAR AND INTERIM -  
NOVEMBER 26, 2002

\* Clinical studies or other  
research involving humans  
are encouraged

**BADGE ONLY ACCESS TO RESEARCH BUILDINGS**

As a first step in complying with tightening federal and state regulations, all School research buildings are now badge-access only around the clock, effective Sept. 11. Unfortunately, improving security often decreases convenience. Badge-access devices have been installed on most exterior doors of the Gray Building, the Hanes Research Building and the Center for Research on Nutrition and Chronic Disease Prevention; the rest of the doors will provide exit only. All Medical Center badges will work to gain access and will record entries into the buildings. Interior doors between Watlington and Gray, and North Tower and Gray, have also been equipped with badge-access devices. Carpenter Library and the main entrance to Biomedical Communications will be outside the controlled area. New doors that will open only by badge have been installed on the first floor of the Gray building between the original Bowman Gray wing and the James A. Gray wing. The connector between Gray and West on the second, third and fourth floors will be closed, though it will continue to offer exit from the Gray Building. Remember, in order to make this security effort work, we each must be careful to query those without badges who may be in research areas. A process is now being developed which will provide a restricted access badge to those who have legitimate business but may not be faculty or staff. If you have difficulty gaining access with your badge, call Chris Scott at 32313. If you have comments or concerns, call John Williams at 32309 or David Brown at 69375.

**INTRAMURAL FUNDING OPPORTUNITY****Comprehensive Cancer Center of Wake Forest University****Cancer Research Grants for Young Investigators**

The CCCWFU is offering cancer research seed monies to basic and clinical young scientists. Instructors and Assistant Professors without current peer-reviewed funding are eligible. Awards are for up to \$20,000. Preference will be given to cancer research focused in nutrition; psychosocial/behavioral problems; socioeconomically disadvantaged populations; and technology transfer from basic to clinical science. Forms and instructions can be obtained from Bobbie Lindsay, 65392 or [blindsay@wfubmc.edu](mailto:blindsay@wfubmc.edu).

**Deadline:** October 15, 2002

## DEAR DR. OR

Dear Dr. OR:

Is the Summary Statement [critique; pink sheet] for my NIH grant application available to anyone who requests it from NIH under the Freedom of Information Act [FOIA]?

Signed,  
Concerned

Dear Concerned:

No. This has always been the view of those inside and outside of NIH. This opinion has just been affirmed by a U.S. court which "ruled that the summary, containing an evaluation of the agency's review of the merits of an application for NIH funding, constituted a 'predecisional memorandum protected from disclosure under the deliberative process privilege' under FOIA." The trial court went on to say "that the documents were exempt from disclosure under FOIA exemption five, which includes reports and papers that reflect predecisional deliberations and that would not be subject to discovery by a private litigant." Consequently, your Summary Statement will not be shared by NIH with anyone else but you.

Dear Dr. OR:

I noticed the current FDA Form 1572 has an expiration date of 9/30/02. Will this void all the 1572s I have already signed? Where can I get a new form?

Signed,  
Expiring Quickly

Dear Expiring:

According to the FDA, the expiration date at the top of the 1572 pertains to the OMB (Office of Management and Budget) approval for the form. All Federal government agencies must get approval from OMB to collect any information. These OMB approvals are periodically renewed, even if the form itself has not changed. The FDA will be requesting renewal of the 1572 in the near future, which will then be available on the FDA web site. This renewal will not void a 1572 for a study for which the form had been previously submitted.

Dear Dr. OR:

I understand that the School has changed insurance companies. Do I need to make any changes to my consent forms that contain the standard Wake Forest University School of Medicine liability language?

Signed,  
Insuring Appropriate Research

Dear Insuring:

The Wake Forest University School of Medicine maintains limited liability insurance coverage to provide for the treatment of research related injuries that occur as a result of participation in non-industry sponsored research (e.g. NIH or Departmental). The provider of this insurance coverage has changed to the Steadfast Insurance Company. The standard language to be included in consent forms for non-industry sponsored research has been modified to reflect this change and should be used in all new consent forms. The standard language can be found in the IRB Operational Policy and Procedure on Research Related Injury located on the IRB web page ([http://www.wfubmc.edu/or/comm\\_irb.html](http://www.wfubmc.edu/or/comm_irb.html)) Existing consent forms will need to have the new language inserted before the consent form is submitted for continuing review. For existing consent forms, investigators are encouraged to incorporate the new liability language into the existing consent the next time they amend their consent form.

Questions for Dr. OR should be submitted in writing to Amy Comer, Office of Research, or by e-mail: [acomer@wfubmc.edu](mailto:acomer@wfubmc.edu)

## POSITION AVAILABLE

CLINICAL RESEARCH MANAGER, DEPT OF PUBLIC HEALTH SCIENCES. PROVIDE OVERALL ADMINISTRATIVE DIRECTION AND COORDINATION FOR POLICIES, PROCEDURES, AND PROGRAMS FOR MULTIPLE RESEARCH STUDIES AND CLINICS IN THE DEPARTMENT OF PUBLIC HEALTH SCIENCES. MINIMUM QUALIFICATIONS: MASTER'S DEGREE; 3 YEARS OF RELEVANT EXPERIENCE. CONTACT WFUHS HUMAN RESOURCES DEPARTMENT.

## Women's Health Educational and Research Opportunities for Clinicians and Scientists

---

*For upcoming conferences and lectures, visit  
our calendar website at  
[www.wfubmc.edu/women](http://www.wfubmc.edu/women)*

### LAST CALL FOR REGISTRATIONS: 8TH ANNUAL GRAYLYN CONFERENCE OCT. 10-11

This year's Graylyn Conference on Women's Health, entitled "Hormone Replacement Therapy and Coronary Heart Disease: Primary versus Secondary Prevention," is fast approaching. The brochure and registration form can be seen and printed out at our page on the Women's Health Center of Excellence website <http://www.wfubmc.edu/women/profed/brochure.pdf>, or call Allie Richardson at 6-9124 to receive a brochure or to answer any questions. Registration deadline is October 1, 2002.

### CONGRATULATIONS!

The Women's Health Center of Excellence would like to congratulate three of its faculty who were recognized recently for their work.

Dr. Kathleen Grant is this year's WFUHS Established Investigator in Basic Sciences, nominated by her peers on the faculty in recognition of her pioneering work on alcohol, its metabolism and neurochemical effects, and substance-abuse policy. Dr. Shari Barkin is co-recipient of the WFUHS New Investigator in Clinical Sciences award. Both will receive their award at the 6th Annual Faculty Research Awards Day on Friday, September 27.

Dr. Carol Shively has received the 11<sup>th</sup> Annual Award for Excellence in Research from the National Association for Women's Health. She will receive this award on November 8 at the organization's Executive Summit.

Please join us in congratulating these women for their achievements.

### UPCOMING EVENTS:

#### **Breast Cancer Treatment and Quality of Life: Studies in Premature Menopause and Lymphedema**

**Tuesday, October 1, Noon  
Sticht Center Auditorium.**

Presented by Jeanne A. Petrek, MD, Director, Surgical Program, The Lauder Breast Center, Memorial Sloan Kettering

#### **14<sup>th</sup> Annual Western North Carolina William C. and Teperance G. Conley Cancer Conference**

**October 18-19, 2002**

**The Grove Park Inn, Asheville, NC.**

Contact: [dwall@radtherapyassoc.com](mailto:dwall@radtherapyassoc.com)

#### **Gender Aspects of Pain - The GAP Friday November 15, 2002**

**Baltimore Marriott Inner Harbor Hotel**

The last few years have seen a dramatic increase in scientific scrutiny of sex-related factors that may impact pain sensitivity, as well as investigations into pain conditions that demonstrate a higher prevalence in women. This symposium will bring together the recent research work in this area and attempt to bridge information from both laboratory and clinical science.

Phone: 410-706-2866

Email: [whrg@epi.umaryland.edu](mailto:whrg@epi.umaryland.edu)

**Women's Health Continued.....****APGO/PFIZER WOMEN'S HEALTH CURRICULUM DEVELOPMENT AWARD**

An educational grant from Pfizer Women's Health has made it possible for the Medical Education Foundation of the Association of Professors of Gynecology and Obstetrics (APGO) to fund a significant women's health curricular development project, focused at the undergraduate level, by faculty members within a department of obstetrics at an accredited medical school in the United States or Canada.

Proposed projects should involve curriculum development related to women's health medical student education, intent on enhancing the leadership role of the department of obstetrics and gynecology. Awardees are encouraged to work with multidisciplinary faculty, but the project must be based in the department of obstetrics and gynecology. Some of the issues that could be addressed within the scope of this program include evaluation of existing curricula and the development of new interdisciplinary curricula. Examples include

- implementing women's health segments into existing courses;
- investigating interdisciplinary activities in women's health care education at the undergraduate medical school level;
- identifying and responding to the needs of obstetrics and gynecology departments in women's health care education;
- evaluating elective courses in the fourth year; and
- promoting interdisciplinary research that supports development and coordination of process and content in women's health curriculum.

**Contact:**

Donna D. Wachter, Executive Director  
APGO Medical Education Foundation  
2130 Priest Bridge Drive, Suite 7  
Crofton, MD 21114  
Phone: (410) 451-9560  
Email: [dwachter@apgo.org](mailto:dwachter@apgo.org)

**UNAUTHORIZED USE OF LEUKEMIA INHIBITORY FACTOR**

Leukemia Inhibitory Factor (LIF) is an important tool commonly used in stem cell research and in the generation of knockout mice. The human and mouse LIF DNA sequences and expressed recombinant human and mouse proteins are subject to worldwide patent protection, and Chemicon International is the exclusive worldwide licensee for human and mouse LIF for research applications. Presently, there exist several unlicensed cell lines that produce human and mouse LIF that are available in the research community. These cell lines are being transferred to research institutions without the consent of Chemicon or the patent owner. If your laboratory is using any cell line to produce LIF for research or contract services, you may be at risk of patent and exclusive rights infringement. Call the Office of Research if you have questions.

# NEWS FROM NIH

---

## NIH NON-COMPETING GRANT PROGRESS REPORT NOTIFICATION PROCESS

NIH has transitioned the notification of Non-Competing Grant Progress Reports from a hard copy mailing of preprinted PHS 2590 and PHS 416-9 face pages to an electronic format. Starting with the October 1, 2002 deadline, grantees will need to access the NIH website to determine which progress reports are due. Once visiting the NIH website, [http://era.nih.gov/userreports/ipf\\_com.cfm](http://era.nih.gov/userreports/ipf_com.cfm), users will need to enter the Schools IPF code, 9021205, to gain access to the report area.

The Office of Research will monitor this website monthly to determine which progress reports are due from WFUHS. An electronic notification will be sent to the PI that will include the following:

- Grant Number
- Due Date
- Links to Forms [http://www.wfubmc.edu/or/aa\\_nih.html](http://www.wfubmc.edu/or/aa_nih.html)
- Links to Institute/Center addresses  
[http://grants.nih.gov/grants/type5\\_mailing\\_addresses.htm](http://grants.nih.gov/grants/type5_mailing_addresses.htm)

The Office of Research will continue to send these notifications at least two months prior to the deadline. Please note, since there will no longer be a pre-printed face page sent from NIH, a generic progress report facepage is available via the Office of Research website. This facepage is populated with WFUHS information and lacks only grant award specific information. If you have any questions regarding this process, please contact Ryan Favreau, 35306.

\*\*\*\*\*

## NATIONAL SCIENCE FOUNDATION

The NSF has published a revised Grant Proposal Guide (GPF-NSF03-2) that is effective for proposals submitted on or after October 1, 2002. The revisions include important changes that will affect the review of proposals. Additional changes include the recently announced Fastlane enhancements for proposal file updates and withdrawals. A copy of the new GPG including a summary of significant changes is available at <http://www.nsf.gov/pubs/2003/nsf032/gpg032.pdf>.

## AMERICAN LUNG ASSOCIATION

**POSITION:** Research Grants

**DESCRIPTION:** The following awards are available from the Association. All awards are for up to \$35,000 per year for up to two years. Applicants for each award must hold a doctoral degree, faculty appointment and have completed two years of post-doctoral research training. Established investigators or investigators holding large grant awards (eg. NIH-R01) are not eligible.

**Clinical Research Grant** - The objective of this award is to support investigators working in patient-focused research. The areas of research may include the disciplines of health services research, behavioral research, epidemiology, pharmacology, and medical ethics. The outcome of these research activities is to develop new insights into clinical, social, behavioral, and biological factors that affect the manifestation of lung health and disease.

**Research Grant** - The objective of this award is to provide support to investigators whose research is related to pathogenic mechanisms or lung biology.

**Dalsemer Research Grant** - This award is supported by an endowment established by the John A. Hartford Foundation, the Wheelabrator Foundation and Mr. Leonard Dalsemer, all of which support research in interstitial lung disease.

**ALA/LAM Foundation Research Grant** - The objective of this award is to provide seed money to investigators seeking to understand the abnormal smooth muscle proliferation that occurs in Lymphangioliomyomatosis (LAM). The award supports clinical, laboratory, epidemiological, or any other kind of research that directly relates to LAM.

**ALA/Pulmonary Fibrosis Foundation Research Grant** - The primary mission of the Pulmonary Fibrosis Foundation is to improve the quality of life of those affected by this terrible disease. This award is to provide seed money to investigators seeking to understand pulmonary fibrosis. Areas of interest are studies in pathogenesis, genetics, novel therapies, and epidemiological investigation.

Electronic submission is required. Additional information can be found at <http://www.lungusa.org/research/>.

**DEADLINE:** November 1, 2002

### NORTH CAROLINA BIOTECHNOLOGY CENTER

**POSITION:** Institutional Development Grants Program

**DESCRIPTION:** This program supports large-scale projects and programs such as the recruitment of outstanding faculty; the purchase of large, multi-user equipment; and the establishment of cross-disciplinary and multi-institutional research programs. More information can be found at: <http://www.ncbiotech.org/programs/grants.cfm>.

**DEADLINE:** October 4, 2002

# Research Funding Opportunities

For all funding information contact Nancy Murray, Office of Research, 62382, unless noted otherwise in the funding announcement

# Research Funding Opportunities

For all funding information contact Nancy Murray, Office of Research, 62382, unless noted otherwise in the funding announcement

## NATIONAL SCIENCE FOUNDATION

**POSITION:** Graduate Research Fellowship Program

**DESCRIPTION:** The Foundation awards fellowships to support graduate study in science, mathematics, and engineering. Fellowships are intended for individuals who are in the early stages of their graduate study. Fellowships are awarded for graduate study leading to research-based masters or doctoral degrees in fields supported by the NSF, including the mathematical, physical, biological, behavioral and social sciences; engineering; the history of science and the philosophy of science; and for research-based Ph.D. degrees in science education. Fellowships include a \$21,500 stipend for twelve-month tenure; cost-of-education allowance of \$10,500 per tenure year; and a one-time \$1,000 International Research Travel Allowance.

**DEADLINE:** November 7, 2002

## NICHD, NIDCD, NINDS

**POSITION:** Pharmacological Approaches to Enhance Neuromodulation in Rehabilitation - HD-02-023

**DESCRIPTION:** Pharmacological compounds have the potential to enhance functional recovery in rehabilitation, especially when used in conjunction with behavioral and physical therapy. This RFA supports studies relevant to the treatment of neurological conditions such as stroke, brain trauma, spinal cord injury, neurodevelopmental and neurodegenerative disorders, infections, and neurosurgery. Applications in response to this RFA must focus on rehabilitative strategies rather than the reduction of acute pathology. They may include studies involving synaptic plasticity, neurotransmitter interactions, neurotrophic mechanisms, pain or fatigue, or any other neurological mechanisms that accelerate the recovery process, enhance function or reduce disability. Studies in validated animal models may be proposed, provided they include appropriate functional outcomes. Pilot clinical trials in humans may also be considered. This RFA will use the NIH Research Project Grant (R01) and the Exploratory/Developmental Research Grant (R21) award mechanisms.

**DEADLINE:** October 25, 2002

## NINDS

**POSITION:** Mentored Research Scientist Development Awards in Translational Research - PAR-02-140

**DESCRIPTION:** The goal of this PA is to announce a career development opportunity for new investigators to build a program of translational research in neurological disorders under the guidance of an experienced mentor. The research project for this award must specifically be in the area of translational research. Translational research is the process of applying ideas, insights, and discoveries generated through basic scientific inquiry to the treatment or prevention of human disease. The overall objective of this program is to attract and encourage investigators at the postdoctoral or early faculty development stage to focus their efforts on translational research in neurological disorders. This PA will use the NIH Research Scientist Development Award - Research & Training (K01) mechanism.

**DEADLINES:** February 1 and June 1, 2003

## NINDS

**POSITION:** Exploratory/Developmental Projects in Translational Research - PAR-02-138

**DESCRIPTION:** NINDS encourages translational research projects that focus on neurological disorders. Translational research is the process of applying ideas, insights, and discoveries generated through basic scientific inquiry to the treatment or prevention of human disease. This PA requests applications for exploratory/developmental projects intended to discover potential targets for therapeutic intervention, to identify candidate therapeutics, or to develop assays, animal models, devices, or technologies for screening or developing therapeutics. Such projects, if successful, should lead directly to a therapy development project for a particular neurological disorder. This PA will use the NIH Exploratory/Developmental Grant (R21) award mechanism.

**DEADLINES:** February 1 and June 1, 2003

## NIAMS, NIA, NICHD, NINDS

**POSITION:** Precursor Cells in Skeletal Muscle Repair and Hypertrophy - PA-02-136

**DESCRIPTION:** The Institutes encourage investigator-initiated research grant applications to isolate, characterize, and identify precursor cells required for normal growth and repair of injured, aged, or diseased muscle. Goals include determining factors responsible for migration, proliferation, and differentiation of precursor cells following muscle injury or increased exercise. This includes characterizing molecular controls responsible for the quiescence of muscle satellite cells and determining metabolic and motile properties of satellite cells while they are quiescent. Researchers are encouraged to develop strategies using muscle satellite and stem cells in therapies for human disease and enhanced repair of muscle injury and as cellular vectors of genes. This PA will use the NIH individual research project grant (R01) award mechanism.

**DEADLINES:** February 1 and June 1, 2003

## NIA, NIDCD, NIDCR, NIDDK

**POSITION:** Age-Related Changes in Tissue Function: Underlying Biological Mechanisms - PA-02-128

**DESCRIPTION:** This PA is to solicit applications on biological mechanisms of aging in tissue and organs. Projects are encouraged that significantly advance basic biology research to understand how and why changes take place in tissues with age and how those changes relate to altered tissue and organ function. Projects that focus on molecular aspects, as well as cellular aspects of tissue aging, are encouraged. Projects that emphasize molecular and cellular changes that are common among tissues with aging are also encouraged, as are projects that compare mechanisms of aging change in different tissues. Projects must have a clear relevance to aging. The mechanism of support for this PA will be the NIH individual research project grant (R01).

**DEADLINES:** February 1 and June 1, 2003

# Research Funding Opportunities

For all funding information contact Nancy Murray, Office of Research, 62382, unless noted otherwise in the funding announcement

# Research Funding Opportunities

For all funding information contact Nancy Murray, Office of Research, 62382, unless noted otherwise in the funding announcement

## NHLBI

**POSITION:** Ancillary Pharmacogenetics Studies in Heart, Lung, Blood and Sleep Disorders - HL-03-001

**DESCRIPTION:** The goal of this RFA is to conduct pharmacogenetic studies in ongoing or completed clinical trials/studies related to heart, lung, blood, and sleep disorders. Specifically, the RFA focuses on the collection and utilization of DNA from study participants to examine genetic influences on inter-individual differences in prescription drug response. Such studies may help elucidate basic mechanisms of drug effects and adverse reactions and may facilitate optimal selection of therapy in individual patients as well as mitigating serious adverse response or lack of response to therapy. This RFA will use the NIH Individual Research Project (R01) award mechanism.

**DEADLINES:**

Letter of Intent - December 17, 2002

Full Application - January 14, 2003

## NIDDK, NEI, NINR, AHRQ, CDC

### AMERICAN DIABETES ASSOCIATION (ADA)

**POSITION:** Translational Research for the Prevention and Control of Diabetes - PA-02-153

**DESCRIPTION:** The Institutes and the ADA solicit research to translate recent advances in the prevention and treatment of type 1 or type 2 diabetes into clinical practice for individuals and communities at risk. Applications are being sought for clinical or behavioral studies to develop and test improved methods of health care delivery to patients with or at risk of diabetes; improved methods of diabetes self management, and cost effective community-based strategies to promote healthy lifestyles that will reduce the risk of diabetes and obesity. Studies should focus on testing strategies for achieving objectives that have already been proven beneficial, such as control of glycemia and other risk factors for diabetic complications, including hypertension and dyslipidemia and altering life style to prevent or delay the onset of type 2 diabetes in at risk populations, including children and adolescents. Of particular interest are interventions that focus on translating new advances into practice in underserved and minority populations. This PA will use the NIH research demonstration and dissemination project (R18) award mechanism.

**DEADLINES:** February 1 and June 1, 2003

## NIDDK, NIAID, NEI, NHLBI

**POSITION:** Bench to Bedside Research on Type 1 Diabetes and its Complications - DK-03-001

**DESCRIPTION:** The Institutes invite applications involving partnerships between clinical and basic biomedical researchers with the goal of translating advances in our understanding of the molecular basis of type 1 diabetes and its complications into new therapies for the prevention, treatment and cure of this disease. In these "bench to bedside" research partnerships, a team of clinical and basic scientists will conduct collaborative research that, if successful, will bring basic research advances from the laboratory to a point where a potential new therapy can be tested in patients or in preclinical studies in animal models. The overall objective of this RFA is to stimulate translational diabetes research by encouraging the formation of collaborative research teams composed of basic and clinical scientists focused on specific projects that have the potential to develop new therapies for type 1 diabetes or its complications. Applications must involve a team of clinical and basic scientists from a single or multiple institutions. Applications should focus on developing and testing methods for the prevention, cure or improved treatment of type 1 diabetes or its complications. Support for this program will be through the NIH Exploratory/Development Research Grant (R21), the Exploratory/Development Research Grant Phase 2 (R33), and the Phased Innovation Award (R21/R33 combined).

**DEADLINES:**

Letter of Intent - January 29, 2003

Full Application - February 26, 2003

## NIDCD

**POSITION:** Investigator-Initiated Clinical Trials - PA-02-157

**DESCRIPTION:** The objective of this PA is to encourage the submission of investigator-initiated phase III clinical trials related to disorders of hearing, balance, smell, taste, voice, speech and language. Progress in basic research, with expanding knowledge of biological and other factors influencing disease initiation, progression and response to treatment affords an unparalleled opportunity to translate these advances into interventions that can improve the health of the population. This initiative is designed to encourage the development and implementation of protocols examining the efficacy of interventions aiming to treat or prevent disorders of human communication. This PA will use the NIH RO1 award mechanism.

**DEADLINES:** February 1 and June 1, 2003

# Research Funding Opportunities

For all funding information contact Nancy Murray, Office of Research, 62382, unless noted otherwise in the funding announcement

## GRANT AND CONTRACT PROPOSAL WATCH

	This Fiscal Year July - Aug	Last Fiscal Year July - Aug.	% Change
Proposals Submitted	121	135	(10.4)
Dollars Requested	\$26,896,270	\$32,416,117	(17.0)

# Research Funding Opportunities

For all funding information contact Nancy Murray, Office of Research, 62382, unless noted otherwise in the funding announcement

## NHLBI

**POSITION:** Career Transition Award (K22) - PAR-02-154

**DESCRIPTION:** The overall goals of this program are to enable outstanding individuals to obtain a research training experience in the NHLBI Division of Intramural Research and to facilitate their successful transition to an extramural environment as independent researchers. The award will provide up to three years of support for research training in an NHLBI intramural laboratory followed by two years of support for an independent research project in an extramural institution. It is anticipated that awardees will subsequently obtain research project grants such as an R01 to support the continuation of their work.

**DEADLINES:** February 1 and June 1, 2002

### KEY FOR DEPARTMENT OF HEALTH AND HUMAN SERVICES

**(DHHS) INSTITUTES - (<http://www.nih.gov/icd/>)**

**AHRQ** - Agency for Healthcare Research and Quality

**NCCAM** - National Center for Complementary and Alternative Medicine

**NCI** - National Cancer Institute

**NCNR** - National Center of Nursing Research

**NCRR** - National Center for Research Resources

**NEI** - National Eye Institute

**NHLBI** - National Heart, Lung and Blood Institute

**NHGRI** - National Human Genome Research Institute

**NIAAA** - National Institute on Alcohol Abuse and Alcoholism

**NIA** - National Institute on Aging

**NIAID** - National Institute of Allergy and Infectious Diseases

**NIAMS** - National Institute of Arthritis and Musculoskeletal and Skin Diseases

**NIBIB** - National Institute of Biomedical Imaging and Bioengineering

**NICHD** - National Institute of Child Health and Human Development

**NIDA** - National Institute on Drug Abuse

**NIDCD** - National Institute on Deafness and Other Communication Disorders

**NIDDK** - National Institute of Diabetes and Digestive and Kidney Diseases

**NIDCR** - National Institute of Dental and Craniofacial Research

**NIEHS** - National Institute of Environmental Health Sciences

**NIGMS** - National Institute of General Medical Sciences

**NIMH** - National Institute of Mental Health

**NINDS** - National Institute of Neurological Disorders and Stroke

**NLM** - National Library of Medicine

**ORWH** - Office of Research on Women's Health

#### PURSUIT STAFF

SHEILA VRANA, PH.D.

DAVID LYONS, PH.D.

AMY COMER

